{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:57:10Z","timestamp":1791572230909,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5-6","funder":[{"name":"Department of Defense, Defense Health Agency","award":["# HU0001-11-1-0023"],"award-info":[{"award-number":["# HU0001-11-1-0023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although the association between semaglutide use for diabetes or obesity and non-arteritic ischemic optic neuropathy (NAION) has been investigated, the relative risk has not been established in large, racially diverse populations. Given the increasing use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications, it is vital to study the odds of this serious adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study to investigate the relationship between semaglutide use and NAION in Military Health System beneficiaries ages 18 and older with diabetes or overweight and obesity who received care from December 7, 2017 to September 30, 2023. A subset analysis was performed using phosphodiesterase-5 inhibitors. This study was carried out as part of the Burden of Diseases and Injuries in the U.S. Military Health System, 2001-2018: Incidence, Prevalence, and Years Lived project and was found exempt by the Institutional Review Board at the Uniformed Services University of the Health Sciences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,212,775 individuals (973,529 patients with type 2 diabetes and 239,246 with overweight or obesity) were included. There were 2,447 NAION events identified. After adjusting for comorbidities, patients with type 2 diabetes prescribed semaglutide had a significantly lower risk of NAION (OR\u2009=\u20090.36, 95% CI\u2009=\u20090.25-0.51) compared to those prescribed non-GLP-1 RA medications. Among patients who had overweight or obesity, there was no significant difference in the odds of receiving a NAION diagnosis (OR\u2009=\u20090.10, 95% CI\u2009=\u20090.01-1.35). Use of phosphodiesterase-5 inhibitors was associated with lower odds of NAION in both populations (Type 2 diabetes: OR\u2009=\u20090.78, 95% CI\u2009=\u20090.69-0.87; overweight\/obesity: OR\u2009=\u20090.49, 95% CI\u2009=\u20090.26-0.93) compared with those who did not use these medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective cohort study found a lower risk of NAION in patients with type 2 diabetes taking semaglutide compared with those taking non-GLP-1 RA medications in a large, diverse population. There was no association between NAION and semaglutide use in patients with overweight or obesity. These findings suggest that the risk of NAION should not preclude the use of this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/milmed\/usaf522","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:32:21Z","timestamp":1762875141000},"page":"e1020-e1025","source":"Crossref","is-referenced-by-count":7,"title":["Semaglutide Decreases Risk of Non-Arteritic Anterior Ischemic Optic Neuroapthy in Type 2 Diabetic Patients"],"prefix":"10.1093","volume":"191","author":[{"given":"Rachel A","family":"Lieberman","sequence":"first","affiliation":[{"name":"Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]},{"name":"Walter Reed National Military Medical Center , Bethesda, MD 20814,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-5171","authenticated-orcid":false,"given":"Jessica","family":"Korona-Bailey","sequence":"additional","affiliation":[{"name":"Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]},{"name":"The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc , Bethesda, MD 20817,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-1229","authenticated-orcid":false,"given":"Amanda","family":"Banaag","sequence":"additional","affiliation":[{"name":"Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]},{"name":"The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc , Bethesda, MD 20817,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Furhman","sequence":"additional","affiliation":[{"name":"Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richele","family":"Corrado","sequence":"additional","affiliation":[{"name":"Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey Perez","family":"Koehlmoos","sequence":"additional","affiliation":[{"name":"Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026050517475594400_usaf522-B1","volume-title":"StatPearls","author":"Raizada","year":"2024"},{"key":"2026050517475594400_usaf522-B2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ophtha.2024.01.011","article-title":"Ophthalmic and systemic factors of acute nonarteritic anterior ischemic optic neuropathy in the Quark207 treatment trial","volume":"131","author":"Kupersmith","year":"2024","journal-title":"Ophthalmology"},{"key":"2026050517475594400_usaf522-B3","doi-asserted-by":"publisher","first-page":"618353","DOI":"10.3389\/fmed.2021.618353","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large scale meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026050517475594400_usaf522-B4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026050517475594400_usaf522-B5","doi-asserted-by":"publisher","first-page":"24318574","DOI":"10.1101\/2024.12.09.24318574","author":"Simonsen","year":"2024"},{"key":"2026050517475594400_usaf522-B6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-World evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"2026050517475594400_usaf522-B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"2026050517475594400_usaf522-B8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.esxm.2018.03.001","article-title":"The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis","volume":"6","author":"Liu","year":"2018","journal-title":"Sex Med"},{"key":"2026050517475594400_usaf522-B9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"2026050517475594400_usaf522-B10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026050517475594400_usaf522-B11","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"2026050517475594400_usaf522-B12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050517475594400_usaf522-B13","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026050517475594400_usaf522-B14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamaophthalmol.2024.2514","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"142","author":"Mollan","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026050517475594400_usaf522-B15","author":"Research C for DE and Vardenafil hydrochloride (marketed as Levitra) Information","year":"2018"},{"key":"2026050517475594400_usaf522-B16","doi-asserted-by":"publisher","first-page":"e27642","DOI":"10.7759\/cureus.27642","article-title":"Non-arteritic anterior ischemic optic neuropathy associated with the use of phosphodiesterase type 5 inhibitors: a literature review","volume":"14","author":"Hor","year":"2022","journal-title":"Cureus"},{"key":"2026050517475594400_usaf522-B17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamasurg.2018.0480","article-title":"Practical guide to surgical data sets: military health system tricare encounter data","volume":"153","author":"Schoenfeld","year":"2018","journal-title":"JAMA Surg"},{"key":"2026050517475594400_usaf522-B18","doi-asserted-by":"publisher","first-page":"100487","DOI":"10.1016\/j.xkme.2022.100487","article-title":"Prevalence and characteristics of CKD in the US military health system: a retrospective cohort study","volume":"4","author":"Oliver","year":"2022","journal-title":"Kidney Med"},{"key":"2026050517475594400_usaf522-B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40337-024-00990-5","article-title":"Association between body composition standards and eating disorder medical claims among active-duty service women","volume":"12","author":"Korona-Bailey","year":"2024","journal-title":"J Eat Disord"},{"key":"2026050517475594400_usaf522-B20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1186\/s12889-023-16460-7","article-title":"A cohort study of BMI changes among U.S. Army soldiers during the COVID-19 pandemic","volume":"23","author":"Wuerdeman","year":"2023","journal-title":"BMC Public Health"},{"key":"2026050517475594400_usaf522-B21","doi-asserted-by":"publisher","first-page":"e2420393","DOI":"10.1001\/jamanetworkopen.2024.20393","article-title":"Development of chronic pain conditions among women in the military health system","volume":"7","author":"Schoenfeld","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026050517475594400_usaf522-B22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jvs.2013.05.008","article-title":"Comparative methods for handling missing data in large databases","volume":"58","author":"Henry","year":"2013","journal-title":"J Vasc Surg"},{"key":"2026050517475594400_usaf522-B23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajo.2023.03.013","article-title":"Race distribution in nonarteritic anterior ischemic optic neuropathy","volume":"253","author":"Banc","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"2026050517475594400_usaf522-B24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026050517475594400_usaf522-B25","author":"Boban","year":"2024"},{"key":"2026050517475594400_usaf522-B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/EB.S9078","article-title":"Energy metabolism of the visual system","volume":"2","author":"Wong-Riley","year":"2010","journal-title":"Eye Brain"},{"key":"2026050517475594400_usaf522-B27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/WNO.0000000000002163","article-title":"Validity of administrative coding for nonarteritic ischemic optic neuropathy","volume":"44","author":"Hamedani","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"2026050517475594400_usaf522-B28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/WNO.0000000000001805","article-title":"Accuracy of international classification of diseases codes for identifying acute optic neuritis","volume":"43","author":"Muro-Fuentes","year":"2023","journal-title":"J Neuroophthalmol"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/5-6\/e1020\/65269940\/usaf522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/5-6\/e1020\/65269940\/usaf522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:18:32Z","timestamp":1778019512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/191\/5-6\/e1020\/8320596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":28,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2026,4,16]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaf522","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,16]]}}}